Overview
The iLet Bionic Pancreas from Beta Bionics is the world's most autonomous closed-loop insulin delivery system. Unlike conventional insulin pumps and even other AID (Automated Insulin Delivery) systems that require users to enter carbohydrate counts, set basal rates, or program correction boluses, the iLet requires only one input at startup: the user's body weight.
From that single data point, the iLet's proprietary ML algorithm learns each individual's insulin needs over the first 2–3 days and adapts continuously thereafter — dosing insulin in response to CGM glucose readings without any user programming. This approach, called "insulin-only bionic pancreas" therapy, achieved the landmark results of the iDCL pivotal trial.
FDA approved in 2023 for people with T1D aged 6 years and older, the iLet pairs with Dexcom G6 and G7 CGM. The system delivers both meal-time and basal insulin from a single insulin reservoir.
Key Technology
⚖️
Weight-Only Initialization
Zero programming at setup. Enter body weight once; the algorithm calculates starting parameters and begins learning the user's unique insulin response immediately.
🧠
Adaptive ML Algorithm
Stochastic differential equation-based model updates insulin delivery parameters multiple times per hour based on recent CGM patterns, time of day, and historical responses.
🔗
Fully Closed-Loop AID
Delivers both corrective and meal-time insulin autonomously. No announcement required before meals — system detects post-prandial glucose rise and responds automatically.
📡
CGM Integration
Pairs directly with Dexcom G6 and G7 via Bluetooth. Receives glucose readings every 5 minutes and re-evaluates dosing decisions continuously.
Pivotal Trial: iDCL
Pivotal RCT
iDCL Trial — Bionic Pancreas vs Standard of Care
Landmark 13-week RCT (N=326) across 16 US centers. iLet achieved mean HbA1c reduction of 0.5% vs. standard care, with significantly higher TIR (70–180 mg/dL) of 11.1 percentage points. No increase in severe hypoglycemia.
Pediatric Study
iDCL Pediatric Cohort (Ages 6–17)
Pediatric arm of iDCL showed consistent TIR improvement across age groups, supporting the FDA's approval down to age 6. Caregivers reported substantially reduced glycemic burden and overnight anxiety.
Quality of Life
Diabetes Distress Scale Reduction
Secondary endpoint in iDCL showed statistically significant reduction in diabetes distress scores — the first pivotal AID trial to demonstrate PRO benefits in glycemic burden as a co-primary outcome.
Regulatory Timeline
2015
Beta Bionics founded by Dr. Ed Damiano (Boston University)
2019
iDCL pivotal trial begins enrollment across 16 US sites
2022
iDCL results published in NEJM; FDA PMA submission filed
2023
FDA PMA approval for T1D ages 6+; commercial launch begins
2025
T2D indication study ongoing; international regulatory submissions advancing